Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered virus joins forces with immunotherapy to fight resistant cancers

NCT ID NCT04291105

Ongoing Disease control Sponsor: Vyriad, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a modified virus (VV1) combined with the immunotherapy drug cemiplimab can shrink tumors in people with colorectal cancer, head and neck squamous cell carcinoma, or melanoma that has stopped responding to checkpoint inhibitor treatment. The virus is designed to infect and kill cancer cells while also boosting the immune system. The study aims to see how many participants have a significant tumor response and to confirm the safety of the combination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
VV1 (a modified virus) and cemiplimab (an immunotherapy drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with colorectal cancer, head and neck cancer, or melanoma that has stopped responding to standard immunotherapy.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply to everyone. The virus-based therapy may cause side effects, and the combination may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal cancer head and neck squamous cell carcinoma melanoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLO-RECTAL CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA MELANOMA

Contacts and locations

Locations

  • Billings Clinic Montana Cancer Consortium

    Billings, Montana, 59101, United States

  • Hospital Moinhos de Vento

    Porto Alegre, Rio Grande do Sul, 90035-000, Brazil

  • Hospital Sao Rafael

    Salvador, BR, 41253-190, Brazil

  • Hospital de Amor de Barretos

    Barretos, São Paulo, 14.784-400, Brazil

  • INCA

    Rio de Janeiro, Rio de Janeiro, 20231-050, Brazil

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Ochsner Clinic Foundation

    New Orleans, Louisiana, 70121, United States

  • Saint John's Health Center - John Wayne Cancer Institute (JWCI)

    Santa Monica, California, 90404, United States

  • Sanford Cancer Center

    Sioux Falls, South Dakota, 57104, United States

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, 45219, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • Yale University

    New Haven, Connecticut, 06520-8032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.